BEND, Oregon | January 8, 2026 — Arrayjet, a provider of high-throughput microarray printing technologies, has opened its first United States printing suite in strategic collaboration with Grace Bio Labs, enhancing access to advanced microarray services for life science researchers, biotechnology companies, and pharmaceutical developers across the country. The new facility optimizes array printing workflows and supports accelerated research in proteomics, biomarker discovery, and diagnostic assay development at a time when high-quality data and reproducibility are paramount.
Science Significance
The opening of the new printing suite represents a meaningful advancement for the life sciences research community by providing on-site access to Arrayjet’s precision microarray printing systems. Microarrays are essential tools in high-content biological assays, enabling the simultaneous analysis of thousands of biomolecular interactions, including protein binding, antibody characterization, and gene expression profiling. The collaboration with Grace Bio Labs— known for its **high-performance nitrocellulose substrates and assay consumables—ensures that researchers can generate consistent, high-quality arrays that yield reproducible and reliable data critical for pre-clinical studies and translational research. Having a dedicated printing suite within a quality-certified partner facility accelerates access to these technologies, reduces lead times, and supports increased throughput for complex research projects.
Regulatory Significance
From a regulatory perspective, the enhanced printing suite underscores the importance of analytical consistency, traceability, and documented processes—cornerstones of compliance in regulated environments. Microarray data often feed into assay validation activities, which can later be used to support biomarker qualification, companion diagnostic development, and other regulated workflows under GLP/GCP frameworks. The presence of Arrayjet’s suite within an established quality environment means that research organizations can better align their activities with quality management systems and standard operating procedures, laying the foundation for regulatory-ready outputs should these technologies become part of later-stage development programs that support clinical or diagnostic regulatory submissions.
Business Significance
Advertisement
Economically, this strategic expansion positions Arrayjet and Grace Bio Labs to capture growing demand for microarray services among U.S. biotech and pharmaceutical sectors. By establishing a physical presence in Oregon, Arrayjet enhances its service footprint, offering a local solution that reduces logistical complexity and turnaround times for U.S. customers. The collaboration also strengthens Grace Bio Labs’ portfolio by integrating advanced printing capabilities with their consumable products, creating a complementary service ecosystem that may attract long-term partnerships with research institutions and commercial laboratories. This expansion demonstrates a commitment to scalable infrastructure and service diversification that can drive future revenue growth and deepen market penetration in the North American life science research segment.
Patients’ Significance
While not a direct therapeutic advancement, the suite’s operationalization plays an important role in the broader pipeline that ultimately impacts patients. High-quality microarray analyses facilitate biomarker identification and pre-clinical target validation, which are essential for advancing novel drug candidates and diagnostics. By enhancing researchers’ ability to generate robust biological data quickly and reliably, the new facility indirectly supports the acceleration of translational research that can lead to earlier detection of disease, improved patient stratification strategies, and more precise treatment approaches. This upstream infrastructure investment can shorten research timelines, which over the long term helps bring better diagnostics and therapies to patients sooner.
Policy Significance
On the policy front, the expansion of advanced laboratory infrastructure within the United States aligns with broader efforts to strengthen domestic scientific capabilities and reduce dependencies on overseas facilities for critical research services. Policymakers have increasingly emphasized the importance of biotechnology sovereignty, resilient supply chains, and investments in research infrastructure that supports innovation ecosystems. By situating a high-capacity printing suite in Oregon, Arrayjet and Grace Bio Labs contribute to these goals, reinforcing the U.S. research base while expanding access to precision technologies that underpin modern biomedical research and data quality standards.
The launch of Arrayjet’s first U.S. printing suite in collaboration with Grace Bio Labs marks a thoughtful investment in the infrastructure that fuels life science discovery and innovation. By combining advanced microarray printing technology with a quality-oriented partner environment, the service expansion supports researchers’ needs for reliable, high-throughput data generation—a critical enabler for pre-clinical research, biomarker discovery, and translational science. As demand for high-content biological insights continues to grow across biotechnology and pharmaceutical sectors, this strategic collaboration strengthens the research ecosystem and underscores how foundational technologies contribute to the broader goals of scientific progress, regulatory readiness, and better outcomes for patients.
Source: Arrayjet press release
